Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 122 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Clopidogrel 75 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Ex Vivo Human Thrombosis Chamber Study

NCT00935506
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease

NCT01260584
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

NCT01500434
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
21
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

Secondary Prevention of Small Subcortical Strokes Trial

NCT00059306
View directory record Official record
Conditions
Cerebrovascular Accident, Hypertension
Interventions
aspirin, clopidogrel, Target of Blood Pressure, placebo
Drug · Other
Lead sponsor
University of British Columbia
Other
Eligibility
30 Years and older
Enrollment
3,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
39
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Crossover Trial of Clopidogrel and Ticagrelor

NCT03161678
View directory record Official record
Conditions
Myocardial Infarction, Thrombosis, Platelet Dysfunction
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Terminated Phase 4 Interventional Results available

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study

NCT01452152
View directory record Official record
Conditions
Cardiovascular Diseases, Acute Coronary Syndrome
Interventions
clopidogrel, prasugrel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 74 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Newark, Delaware • Baltimore, Maryland • Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 2, 2026, 4:08 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study

NCT01768637
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Targeting Platelets in Chronic HIV Infection

NCT02578706
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Clopidogrel, Aspirin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 2, 2026, 4:08 AM EDT
Not listed Not applicable Interventional

Plavix, Prasugrel and Drug Eluting Stents Pilot Trial

NCT01103843
View directory record Official record
Conditions
Coronary Artery Disease, Platelet Aggregation Inhibitors, PCI- Percutaneous Coronary Intervention
Interventions
Loading Dose Arm, Maintenance Dose Arm
Drug
Lead sponsor
St. Francis Hospital, New York
Other
Eligibility
21 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Oct 2, 2026, 4:08 AM EDT
Completed No phase listed Observational

Replication of the PLATO Antiplatelet Trial in Healthcare Claims Data

NCT04237935
View directory record Official record
Conditions
Antiplatelet
Interventions
Ticagrelor 90mg, Clopidogrel 75mg
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
27,960 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 2, 2026, 4:08 AM EDT
Withdrawn Phase 4 Interventional

The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation

NCT02626169
View directory record Official record
Conditions
Atherosclerosis
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Clopidogrel and Rosuvastatin

NCT01469416
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Clopidogrel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Clopidogrel Pharmacogenomics Project

NCT01097343
View directory record Official record
Conditions
Disease Susceptibility
Interventions
clopidogrel 75 mg, Clopidogrel 150 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects

NCT01129271
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, Matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

NCT01147588
View directory record Official record
Conditions
Healthy
Interventions
lansoprazole, omeprazole, esomeprazole, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

NCT04702113
View directory record Official record
Conditions
Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction, Ischemic Stroke
Interventions
Cipherome Lighthouse Pilot
Diagnostic Test
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI

NCT00751231
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
clopidogrel, PRT060128
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
La Jolla, California • Torrance, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI

NCT03437044
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

NCT02833948
View directory record Official record
Conditions
Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases, Ventricular Outflow Obstruction, Thrombosis
Interventions
Acetylsalicylic acid, Clopidogrel, Rivaroxaban
Drug
Lead sponsor
ECRI bv
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 2, 2026, 4:08 AM EDT
Recruiting Phase 4 Interventional

The Switching Antiplatelet-9 (SWAP-9) Study

NCT06588595
View directory record Official record
Conditions
Coronary Arterial Disease (CAD)
Interventions
Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Recruiting Phase 2 Interventional

A Polypill for Acute Coronary Syndrome

NCT07032389
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Polypill
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Recruiting Phase 4 Interventional

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

NCT06821191
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
clopidogrel 75 mg, Prasugrel 5 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

NCT01789814
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 2, 2026, 4:08 AM EDT